Reuters :: Health

U.S. seeks more data for J&J schizophrenia drug

WASHINGTON (Reuters) - U.S. health regulators have called for more data before deciding whether a Johnson & Johnson experimental schizophrenia drug could be sold on the U.S. market, the company said on Tuesday. <p><a href="http://feeds.feedburner.com/~a/reuters/healthNews?a=sNa6mt"><img src="http://feeds.feedburner.com/~a/reuters/healthNews?i=sNa6mt" border="0"></img></a></p><div class="feedflare"> <a href="http://feeds.feedburner.com/~f/reuters/healthNews?a=mf2s5K"><img src="http://feeds.feedburner.com/~f/reuters/healthNews?i=mf2s5K" border="0"></img></a> <a href="http://feeds.feedburner.com/~f/reuters/healthNews?a=PHDszk"><img src="http://feeds.feedburner.com/~f/reuters/healthNews?i=PHDszk" border="0"></img></a> <a href="http://feeds.feedburner.com/~f/reuters/healthNews?a=pHr7Fk"><img src="http://feeds.feedburner.com/~f/reuters/healthNews?i=pHr7Fk" border="0"></img></a> </div><img src="http://feeds.feedburner.com/~r/reuters/healthNews/~4/375726347" height="1" width="1"/>